Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417699 · ClinicalTrials.gov registry record · Phase 2
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
A Phase 2 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04417699 is a Phase 2 study that has completed, run by Providence Health & Services. The registered enrollment target is 13 participants.
The verdict
NCT04417699, a Phase 2 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery.
Interventions
- DRUG Oxaliplatin
- DRUG TAS 102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417699
The ClinicalTrials.gov registry entry for NCT04417699 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT04417699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04417699 about?
NCT04417699 is a clinical study titled "SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer". TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage II/III rectal cancer patients treated with contemporary TME-based surgery.
What is the current status of trial NCT04417699?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-07-05. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT04417699?
The interventions under investigation include: Oxaliplatin (DRUG), TAS 102 (DRUG).
Who is sponsoring clinical trial NCT04417699?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.